Literature DB >> 8240727

Features, prevention and management of acute overdose due to antidiabetic drugs.

D F Moore1, D F Wood, G N Volans.   

Abstract

Hypoglycaemic medication forms a disparate group of therapeutic compounds including insulin, the sulphonylureas and biguanides. They are all designed to prevent hyperglycaemia and in general are well tolerated. Careful prescribing practice and patient education by the physician can do much to reduce the risk of adverse effects from diabetic therapy. However, the presentation of adverse effects, together with accidental and non-accidental overdose, is a frequent clinical problem. Furthermore, the possible impairment of hypoglycaemic awareness in patients prescribed human insulin has added complexity to diabetic management. The cardinal features of insulin overdose are hypoglycaemia and hypokalaemia. The sulphonylureas predominantly cause hypoglycaemia, while the biguanides may precipitate lactataemia and acidosis. Recognition of hypoglycaemia is therefore crucial in avoidance of toxicity. Intravenous dextrose is the mainstay of therapy following gut decontamination (for the oral agents). The efficacy of glucagon is dependent on hepatic glycogen stores and should therefore be used with caution. Diazoxide is not recommended. More recently, octreotide has been shown to be effective in sulphonylurea overdose. Patients should be admitted and monitored with serial blood sugar measurements for a minimum of 1 to 2 days as clinically warranted.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8240727     DOI: 10.2165/00002018-199309030-00007

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  40 in total

Review 1.  Cellular trafficking and processing of the insulin receptor.

Authors:  V P Knutson
Journal:  FASEB J       Date:  1991-05       Impact factor: 5.191

2.  Human insulin and hypoglycaemia: burning issue or hot air?

Authors:  G Williams; A W Patrick
Journal:  BMJ       Date:  1992-08-08

3.  Metformin and glibenclamide: comparative risks.

Authors:  I W Campbell
Journal:  Br Med J (Clin Res Ed)       Date:  1984-08-04

4.  Plasma levels of glibenclamide in diabetic patients during its routine clinical administration determined by a specific radioimmunoassay.

Authors:  A Matsuda; T Kuzuya; Y Sugita; K Kawashima
Journal:  Horm Metab Res       Date:  1983-09       Impact factor: 2.936

5.  Unawareness of hypoglycaemia in insulin-treated diabetic patients: prevalence and relationship to autonomic neuropathy.

Authors:  D A Hepburn; A W Patrick; D W Eadington; D J Ewing; B M Frier
Journal:  Diabet Med       Date:  1990 Sep-Oct       Impact factor: 4.359

6.  Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents.

Authors:  A M Jennings; R M Wilson; J D Ward
Journal:  Diabetes Care       Date:  1989-03       Impact factor: 19.112

7.  Kinetics of circulating endogenous insulin, C-peptide, and proinsulin in fasting nondiabetic man.

Authors:  J H Henriksen; B Tronier; J B Bülow
Journal:  Metabolism       Date:  1987-05       Impact factor: 8.694

8.  Chlorpropamide overdose in renal failure: management with charcoal hemoperfusion.

Authors:  S M Ludwig; J McKenzie; C Faiman
Journal:  Am J Kidney Dis       Date:  1987-12       Impact factor: 8.860

9.  Hypoglycemia: causes, neurological manifestations, and outcome.

Authors:  R Malouf; J C Brust
Journal:  Ann Neurol       Date:  1985-05       Impact factor: 10.422

Review 10.  Metformin: a review of its pharmacological properties and therapeutic use.

Authors:  L S Hermann
Journal:  Diabete Metab       Date:  1979-09
View more
  3 in total

Review 1.  Drug-induced endocrine and metabolic disorders.

Authors:  Ronald C W Ma; Alice P S Kong; Norman Chan; Peter C Y Tong; Juliana C N Chan
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 2.  Management of antidiabetic medications in overdose.

Authors:  H A Spiller
Journal:  Drug Saf       Date:  1998-11       Impact factor: 5.606

3.  Intentional overdose with insulin: prognostic factors and toxicokinetic/toxicodynamic profiles.

Authors:  Bruno Mégarbane; Nicolas Deye; Vanessa Bloch; Romain Sonneville; Corinne Collet; Jean-Marie Launay; Frédéric J Baud
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.